scholarly journals The future of mucosal HIV vaccines

2011 ◽  
Vol 32 (3) ◽  
pp. 118
Author(s):  
Jeanette Reece ◽  
Stephen Kent
Keyword(s):  
Mucosal Immunity ◽  
Hiv Vaccine ◽  
Cytotoxic T Cell ◽  
Global Public Health ◽  
Efficacy Trial ◽  
Primary Analysis ◽  
Efficacy Trials ◽  
Immunodeficiency Virus ◽  
Public Health Challenge ◽  
Hiv Vaccine Efficacy Trial

Approximately 33 million people live with the human immunodeficiency virus (HIV) and 2.6 million new infections are acquired each yea1. The development of an effective HIV vaccine that induces robust mucosal immunity represents a major global public health challenge. Large human efficacy trials of simple antibody-based and cytotoxic T cell-based vaccines have failed to provide any protection. The recent RV144 HIV vaccine efficacy trial in Thailand using a prime-boost combination of vaccines, however, showed modest efficacy (31%, p=0.04 on the primary analysis). Although the efficacy was marginal, the study has provided considerable hope that a vaccine to prevent infection by HIV may be feasible.

HIV Sexual Risk Behavior Over 36 Months of Follow-Up in the World??s First HIV Vaccine Efficacy Trial

2005 ◽  
Vol 39 (1) ◽  
pp. 90-101 ◽  
Author(s):  
Bradford N Bartholow ◽  
Susan Buchbinder ◽  
Connie Celum ◽  
Vamshidar Goli ◽  
Beryl Koblin ◽  
...  
Keyword(s):  
Risk Behavior ◽  
Sexual Risk ◽  
Sexual Risk Behavior ◽  
Vaccine Efficacy ◽  
Hiv Vaccine ◽  
Efficacy Trial ◽  
The World ◽  
Hiv Sexual Risk ◽  
Hiv Vaccine Efficacy Trial

Negative Social Impacts Among Volunteers in an HIV Vaccine Efficacy Trial

2007 ◽  
Vol 46 (3) ◽  
pp. 362-368 ◽  
Author(s):  
Jonathan Fuchs ◽  
Marcus Durham ◽  
Eleanor McLellan-Lemal ◽  
Eric Vittinghoff ◽  
Grant Colfax ◽  
...  
Keyword(s):  
Vaccine Efficacy ◽  
Social Impacts ◽  
Hiv Vaccine ◽  
Efficacy Trial ◽  
Hiv Vaccine Efficacy Trial

Pregnancies among high-risk women in the first ever HIV vaccine efficacy trial

AIDS ◽  
2003 ◽  
Vol 17 (5) ◽  
pp. 787-788 ◽  
Author(s):  
Pamela Brown-Peterside ◽  
Leigh Ren ◽  
Adrian Hirsch ◽  
Marc Drucker ◽  
Beryl A Koblin
Keyword(s):  
High Risk ◽  
Vaccine Efficacy ◽  
Hiv Vaccine ◽  
Efficacy Trial ◽  
High Risk Women ◽  
Hiv Vaccine Efficacy Trial

Motivations for Participating in an HIV Vaccine Efficacy Trial

2005 ◽  
Vol 39 (3) ◽  
pp. 359-364 ◽  
Author(s):  
Grant Colfax ◽  
Susan Buchbinder ◽  
Goli Vamshidar ◽  
Connie Celum ◽  
David McKirnan ◽  
...  
Keyword(s):  
Vaccine Efficacy ◽  
Hiv Vaccine ◽  
Efficacy Trial ◽  
Hiv Vaccine Efficacy Trial

scholarly journals Does participation in an HIV vaccine efficacy trial affect risk behaviour in South Africa?

Vaccine ◽  
2013 ◽  
Vol 31 (16) ◽  
pp. 2089-2096 ◽  
Author(s):  
G.E. Gray ◽  
B. Metch ◽  
G. Churchyard ◽  
K. Mlisana ◽  
M. Nchabeleng ◽  
...  
Keyword(s):  
South Africa ◽  
Vaccine Efficacy ◽  
Risk Behaviour ◽  
Hiv Vaccine ◽  
Efficacy Trial ◽  
Hiv Vaccine Efficacy Trial

scholarly journals Immunogenicity of a Human Immunodeficiency Virus (HIV) Polytope Vaccine Containing Multiple HLA A2 HIV CD8+ Cytotoxic T-Cell Epitopes

1999 ◽  
Vol 73 (7) ◽  
pp. 5320-5325 ◽  
Author(s):  
T. Woodberry ◽  
J. Gardner ◽  
L. Mateo ◽  
D. Eisen ◽  
J. Medveczky ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Cytotoxic T Lymphocytes ◽  
Recombinant Virus ◽  
Hiv Vaccine ◽  
Cytotoxic T Cell ◽  
T Cell Epitopes ◽  
Immunodeficiency Virus ◽  
Escape Mutants ◽  
Hiv Type 1

ABSTRACT Compelling evidence now suggests that αβ CD8 cytotoxic T lymphocytes (CTL) have an important role in preventing human immunodeficiency virus (HIV) infection and/or slowing progression to AIDS. Here, we describe an HIV type 1 CTL polyepitope, or polytope, vaccine comprising seven contiguous minimal HLA A2-restricted CD8 CTL epitopes conjoined in a single artificial construct. Epitope-specific CTL lines derived from HIV-infected individuals were able to recognize every epitope within the construct, and HLA A2-transgenic mice immunized with a recombinant virus vaccine coding for the HIV polytope also generated CTL specific for different epitopes. Each epitope in the polytope construct was therefore processed and presented, illustrating the feasibility of the polytope approach for HIV vaccine design. By simultaneously inducing CTL specific for different epitopes, an HIV polytope vaccine might generate activity against multiple challenge isolates and/or preempt the formation of CTL escape mutants.

Sign in / Sign up

Export Citation Format

Share Document